CARL
Carlsmed Inc. · NASDAQ
- Market cap
- $486.1M
Carlsmed Inc. (CARL) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for CARL, including 2 earnings updates, 2 insider trades and 2 SEC filings. The most recent was published Nov 16, 2026.
CARL rankings
Financial highlights
Full financials- Revenue, TTM
- $71.78M
- Revenue growth
- +60.4%
- Net income, TTM
- -$40.06M
- Net margin
- -55.8%
- Free cash flow, TTM
- -$34.92M
- Cash
- $35.95M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks38-42%
2026-05-242026-11-15
Mix2690d
- Insider10(38%)
- SEC Filings7(27%)
- Other5(19%)
- Leadership2(8%)
- Earnings2(8%)
Activity · 52 weeks6438 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRCarlsmed to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that management will participate in the following investor conferences: Ninth Annual Evercore Healthcare Conference Format: Fireside chat Date: Monday, November 30, 2026 Time: 12:55 p.m. Eastern time (9:55 a.m. Pacific time) Piper Sandler 38th Annual Healthcare Conference Format: Fireside chat Date: Wednesday, December 2, 2026 Time: 2:30 p.m. Eastern time (11:30 a.m. Pacific time) Live and archived webcasts for these events will be available in the Events & Presentations
- SECSEC Form 10-Q filed by Carlsmed Inc.10-Q - CARLSMED, INC. (0001794546) (Filer)
- SECCarlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year GuidanceThird quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2026. "The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year," sa
- INSIDERChief Operating Officer Bertolini Jeffrey exercised 747 shares at a strike of $5.92 and sold $11,317 worth of shares (747 units at $15.15) as part of a pre-agreed trading plan (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERChief Operating Officer Bertolini Jeffrey exercised 243 shares at a strike of $2.23 and sold $3,839 worth of shares (243 units at $15.80) as part of a pre-agreed trading plan (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- PRCarlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. A live webcast of the conference call will be available in the Events & Presentations section of the Company’s investor website at investors.carlsmed.com. Participants may also join via telephone by registering here. A replay will be archived on the Company’s website follo
- SECSEC Form 144 filed by Carlsmed Inc.144 - CARLSMED, INC. (0001794546) (Subject)
- PRCarlsmed Launches aprevo® Lumbar Bi-lateral Posterior SystemCARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026. "The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion," said Mike Cordonnier, Chairman and CEO of Carlsmed. "The Bi-lateral System is optimized to support pla
- INSIDERChief Operating Officer Bertolini Jeffrey sold $10,749 worth of shares (747 units at $14.39) as part of a pre-agreed trading plan (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- PRCarlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units ("RSUs") to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment. The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony Jarc, the Company’s ne
- INSIDERChief Operating Officer Bertolini Jeffrey sold $3,400 worth of shares (243 units at $13.99) as part of a pre-agreed trading plan and exercised 243 shares at a strike of $2.23 (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- SECSEC Form S-8 filed by Carlsmed Inc.S-8 - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed Appoints Tony Jarc as Chief Product and AI OfficerCARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surgery procedures. "Tony’s addition comes at a pivotal moment as we transform our technology platform to scale and advance our patient-centric innovation for our highly differentiated personalized surge
- INSIDERNew insider Kamocsay Jennifer claimed ownership of 56,222 shares (SEC Form 3)3 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERCFO, Treasurer Heppenstall Richard was granted 89,286 shares (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERSEC Form 3 filed by new insider Heppenstall Richard3 - CARLSMED, INC. (0001794546) (Issuer)
- SECCarlsmed Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed Appoints Richard Heppenstall as Chief Financial OfficerCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests. "We are excited to welcome Rich to Carlsmed at a pivotal point for the Company," said Mike Cordonnier, Chairman and CEO. "He is a proven leader with the deep Orthopedic and Tech expertise crucial to driving our strategy, and his deep financial
- PRCarlsmed, Inc. Files Patent Infringement Lawsuit against DeGen MedicalCARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. ("DeGen") in the United States District Court for the District of South Carolina Florence Division. The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement. "Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing va
- INSIDERAmendment: Large owner Presidio Management Group Xii, L.L.C. bought $3,000,000 worth of shares (200,000 units at $15.00) (SEC Form 4)4/A - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Bertolini Jeffrey4 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERNew insider Bertolini Jeffrey claimed ownership of 22,489 shares (SEC Form 3)3 - CARLSMED, INC. (0001794546) (Issuer)
- SECCarlsmed Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed, Inc. Announces Chief Operating Officer AppointmentCARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company’s Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical. "Jeff has made measurable contributions to our op
CARL FAQ
10 questionsWhat is the latest news on CARL?
In the last 30 days Quantisnow tracked 7 wire items for CARL: 2 earnings updates, 2 insider trades, 2 SEC filings and 1 press release or news item. The most recent was published on November 16, 2026.What is CARL revenue?
Carlsmed Inc. (CARL) reported $71.78M of revenue for the twelve months ended Sep 30, 2026. That is up 60.4% from the year before. Revenue for fiscal 2025 was $50.51M.Is CARL profitable?
No. Carlsmed Inc. reported a net loss of $40.06M for the twelve months ended Sep 30, 2026.How much cash and debt does CARL have?
Carlsmed Inc. reported $35.95M in cash and cash equivalents and $15.40M of debt on its most recent balance sheet in SEC filings.Where does CARL stock trade?
Carlsmed Inc. (CARL) is listed on NASDAQ.What sector and industry is CARL in?
Carlsmed Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Carlsmed Inc. go public?
Carlsmed Inc. (CARL) completed its IPO in 2025.What are analysts saying about CARL?
Carlsmed Inc. has had 6 recent analyst actions on file. The most recent action was from Needham: Buy with a $17.00 price target on 2026-07-01. Recent price targets range from $16.00 to $21.00.What companies are similar to CARL?
Notable peers in the same industry include MMM (3M Company), BSX (Boston Scientific Corporation), DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company). Compare CARL side-by-side with any of them on Quantisnow.How can I track CARL on Quantisnow?
Quantisnow aggregates Carlsmed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CARL to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change